News

Review and meta-analysis identifies clinical manifestations, risk factors, and maternal and perinatal outcomes associated with COVID-19 in pregnancy.

A discussion with an Ohio State investigator on early CMR findings among young athletes.

Investigators resumed phase 3 international assessments after independent committees and regulators deemed it safe to do so.

In another of many hand sanitizer recalls since the start of the pandemic, FDA is working with Medek LLC to remove all lots of “M” hand sanitizer from store shelves.

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

Robert H. Christenson, PhD, University of Maryland, outlines the incentives for how SARS-CoV-2 testing reagents are acquired by institutions.

Robert H. Christenson, PhD, outlines the ways SARS-CoV-2 transmission is prevented during testing, how testing materials are acquired, and more.

A clinical-stage immunology company has an investigational therapy looking to target the tumor necrosis factor cytokine.

Results of the trial of Novavax’s NVX-CoV2373 vaccine have been published in the New England Journal of Medicine, showing the vaccine appeared safe and elicited strong immune responses.

A new study in The Lancet maps trends in vaccine confidence around the world.

New guidance from the Infectious Diseases Society of America offers timely practice advice for the clinical treatment of three of the most common drug-resistant pathogens.

Decision Diagnostics Corp. has submitted 2 applications with the FDA for a COVID-19 testing technology that the firm claims can identify the virus in about 10 seconds.

New research presented at ERS shows how critically ill COVID-19 patients face cardiac and pulmonary burdens weeks after recovery.

The investigational vaccine was regarded as well-tolerated and elicited an immune response.

A new study that compared the results of a behavior intervention program for young adults living with HIV found outcomes were better when the intervention occurred in a clinic rather than at the patients’ homes.

A Rapid Response in BMJ argues that to achieve Zero-COVID, we need to broaden our thinking to include the controlled and careful acquisition of population immunity.

In this segment, Dysphagia expert Rinki Varindani Desai shares her perspective on the need for an adaptive health care system response that incorporates equity across health burdens.

How a Chicago-based surgeon managed an unprecedented procedure for young woman at the height of the pandemic.

An examination of a patient presenting with the condition in the early days of the pandemic without the access to current care protocols.

SARS-CoV-2 is unlikely to pass through the breast milk of infected mothers to their infants, according to a recent evaluation of breast milk samples from 18 women who tested positive for the COVID-19.

The CMS Sepsis Bundle Core Performance Measure of sepsis treatment could contribute to the overuse of broad-spectrum antibiotics

A new report shows a UK-based participant experienced a serious adverse event, but is anticipated to recover.

A total of 9 firms signed the letter promising to put safety at the top of the priority list in ongoing COVID-19 vaccine development projects.

Rising costs from 2014-2018 may have hindered PrEP expansion, according to a recent retrospective study.

A follow-up on analysis from earlier in the pandemic reveals that virulence in children remained stable over a 5-month period.

The story of an early-infected US physician who launched a non-profit, participated in trials, and guided her peers after overcoming infection.

An observational study in the United Kingdom supports the concepts of a hyperinflammation phenotype for severe COVID-19 cases and could help guide risk assessment, precision medicine, and trial design.

In looking at enhancing intervention efforts, where should we do them?